These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37792671)

  • 1. Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.
    Tomonaga Y; de Nijs K; Bucher HC; de Koning H; Ten Haaf K
    Int J Cancer; 2024 Feb; 154(4):636-647. PubMed ID: 37792671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
    Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
    PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
    Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
    JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
    Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
    JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.
    Liu Y; Xu H; Lv L; Wang X; Kang R; Guo X; Wang H; Zheng L; Liu H; Guo L; Chen Q; Liu S; Qiao Y; Zhang S
    BMC Med; 2024 Feb; 22(1):73. PubMed ID: 38369461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
    Tomonaga Y; Ten Haaf K; Frauenfelder T; Kohler M; Kouyos RD; Shilaih M; Lorez M; de Koning HJ; Schwenkglenks M; Puhan MA
    Lung Cancer; 2018 Jul; 121():61-69. PubMed ID: 29858029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
    Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
    Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
    Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
    JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
    Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
    Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
    CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
    Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
    J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Jaine R; Kvizhinadze G; Nair N; Blakely T
    Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
    Kowada A
    BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Based on Start Age and Interval in China: Modeling Study.
    Zhao Z; Du L; Li Y; Wang L; Wang Y; Yang Y; Dong H
    JMIR Public Health Surveill; 2022 Jul; 8(7):e36425. PubMed ID: 35793127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
    Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
    JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.
    Toumazis I; Cao P; de Nijs K; Bastani M; Munshi V; Hemmati M; Ten Haaf K; Jeon J; Tammemägi M; Gazelle GS; Feuer EJ; Kong CY; Meza R; de Koning HJ; Plevritis SK; Han SS
    Ann Intern Med; 2023 Mar; 176(3):320-332. PubMed ID: 36745885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of lung cancer screening combined with nurse-led smoking cessation intervention: A population-based microsimulation study.
    Yuan J; Sun Y; Xu F; Li M; Fan M; Zhang C; Wang K; Li H; Bu X; Yan X; Wang J; Ma J; Zhang G; Chen M; Ren H
    Int J Nurs Stud; 2022 Oct; 134():104319. PubMed ID: 35926265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Tammemägi MC; Darling GE; Schmidt H; Llovet D; Buchanan DN; Leung Y; Miller B; Rabeneck L
    Lung Cancer; 2021 Jun; 156():31-40. PubMed ID: 33887677
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.